0001209191-22-060966.txt : 20221213 0001209191-22-060966.hdr.sgml : 20221213 20221213170420 ACCESSION NUMBER: 0001209191-22-060966 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221209 FILED AS OF DATE: 20221213 DATE AS OF CHANGE: 20221213 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Brumm Joshua T CENTRAL INDEX KEY: 0001528826 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39509 FILM NUMBER: 221460350 MAIL ADDRESS: STREET 1: ZELTIQ AESTHETICS INC. STREET 2: 4698 WILLOW ROAD SUITE 100 CITY: PLEASANTON STATE: CA ZIP: 94588 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Dyne Therapeutics, Inc. CENTRAL INDEX KEY: 0001818794 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 364883909 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1560 TRAPELO ROAD CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781) 786-8230 MAIL ADDRESS: STREET 1: 1560 TRAPELO ROAD CITY: WALTHAM STATE: MA ZIP: 02451 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-12-09 0 0001818794 Dyne Therapeutics, Inc. DYN 0001528826 Brumm Joshua T C/O DYNE THERAPEUTICS, INC. 1560 TRAPELO ROAD WALTHAM MA 02451 1 1 0 0 See Remarks Common Stock 2022-12-09 4 A 0 144000 0.00 A 333123 D Common Stock 2022-12-12 4 S 0 3322 10.87 D 329801 D Stock Option (right to buy) 10.72 2022-12-09 4 A 0 222000 0.00 A 2032-12-08 Common Stock 222000 222000 D Consists of shares of Common Stock issuable under 144,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 10, 2023. Includes 293,544 unvested RSUs. Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. Includes 286,157 unvested RSUs. This option was granted on December 9, 2022. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 10, 2026. Chief Executive Officer and President /s/ Richard Scalzo, Attorney-in-Fact 2022-12-13